Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Sally J. York

Dr. Sally J. York

Medical Oncologist

Dr. Sally York is a medical oncologist and associate professor who treats patients with lung cancer and pleural mesothelioma at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Get in touch
Jump to a Topic:

About Sally J. York

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • 10+ Years of Experience icon

    10+ Years of Experience

  • Board Certified icon

    Board Certified in Medical Oncology

York doubles as a physician/scientist in the Department of Medicine’s Division of Hematology and Oncology. Her laboratory research has focused on genetics and chemotherapy-induced DNA damage by a defective genomic stability pathway in many tumors.

She also serves as the associate director of the Vanderbilt Medical Scientist Training Program, where she works with upcoming leaders in biomedical research.

York arrived in 2012 after more than a decade at Duke University, where she specialized in lung cancer and was also involved in its Medical Scientist Training Program. York completed both her internal medicine residency and oncology fellowship at Duke.

She earned her M.D. and Ph.D. degrees from Washington University in St. Louis and her Bachelor of Science in biochemistry from the University of Iowa. Her doctorate was in molecular cell biology.

Leading Clinical Trials in Cancer Treatment

York plays a significant role in the robust clinical trial program at Vanderbilt, where some of the latest innovative treatments are being studied. She serves as the lead investigator in three clinical trials involving lung cancer.

A phase III trial is studying the effectiveness of erlotinib hydrochloride with non-small cell lung cancer that has been surgically removed. The hope is that the drug can stop any regrowth by blocking certain enzymes that encourage it.

Another phase III trial is using genetic testing on patients whose non-small cell lung cancer has been surgically removed. The belief is that by identifying certain genetic changes, treatment can be more personalized and effective.

Her third clinical trial with non-small cell lung cancer patients is examining the use of the drug crizotinib as a growth inhibitor of a particular protein that fuels tumors marked by a gene mutation.

Improvements in lung cancer treatment often translate into promising research avenues for mesothelioma treatment.

Disclaimer: Dr. Sally J. York has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Vanderbilt Health. (n.d.). Sally J. York, MD, PhD.
    Retrieved from:
  2. Vanderbilt University Medical Center. (2014, June 19). York named Medical Scientist Training Program associate director.
    Retrieved from:
  3. Vanderbilt University Medical Center. (2012, March 8). York named chair of Department of Biochemistry. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified July 31, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now